Loading, Please Wait...
Oversubscribed Early Access Launch Closes with Five DSP Beta Instruments Designated for Leading Academic and Industrial Research Facilities
Now Taking Orders for 2019 Delivery of Commercial GeoMx Digital Spatial Profiler
SEATTLE, Sept. 05, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of the GeoMx™ Priority Site (GPS) program to satisfy the strong demand for the innovative new platform.
The GeoMx Digital Spatial Profiler (DSP) enables researchers to rapidly and quantitatively characterize tissue morphology with a high-throughput, high-plex RNA and protein profiling system that preserves precious samples for future analyses. The GPS Program provides customers the opportunity to be among the first to receive a GeoMx instrument following its expected commercial launch in the first half of 2019, as well as advanced service and support. Inclusion in the GPS Program will also provide researchers, the opportunity to begin generating data on their samples through the Technology Access Program in advance of receiving their GeoMx instrument. GPS status will be limited to the first 20 participants who purchase the commercial system.
“The potential for the GeoMx system to enable a new field of spatial genomics is tremendously exciting,” said Chad Brown, senior vice president of sales & marketing at NanoString. “Demand for the system is high among researchers who recognize the value of this simple, high-throughput method for characterizing the heterogeneity of the tumor micro-environment.”
The launch of the GPS Program was initiated in response to the high level of interest from researchers to participate in the Early Access Launch. Demand from these researchers exceeds the number of beta GeoMx systems available, and all five sites were designated just one month after the Early Access Launch was announced. The Early Access sites span academic research, biopharmaceuticals, and contract research organizations in North America and Europe.
“The GeoMx Digital Spatial Profiler is a powerful platform for biomarker discovery,” said David Rimm, Professor of Oncology and Pathology, Yale University. “GeoMx DSP will be the first commercial platform that enables the analysis of both proteins and RNA at ultra-high plex. We’re excited to be one of the first centers that has the capability to generate spatially resolved RNA and protein data from tumor biopsies.”
The goal of the Early Access Launch is to gather early feedback on the hands-on user experience with DSP. The Early Access Launch will provide each site with a GeoMx beta instrument, high plex RNA and protein assay reagents, and data analysis software. Establishing Digital Spatial Profiling capability at these sites ahead of commercial launch will enable support and completion of high impact projects in addition to enabling feedback to optimize the performance of the platform.
The GeoMx DSP system is currently in development and is expected to be available for early access instrument placements late in 2018 followed by a full commercial launch in 2019. Today, Digital Spatial Profiling technology can be accessed through the Technology Access Program (TAP) announced over a year ago. To date, over 40 customers have completed greater than 55 TAP projects and processed over 1000 samples. The results from these studies highlight the performance of DSP in at least ten abstracts presented at major scientific meetings and several publications in press.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. The GeoMx DSP instrument is currently intended for research use only and is not for use in diagnostic procedures.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, GeoMx, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the performance and attributes of the GeoMx Digital Spatial Profiler, including the commercial availability of GeoMx and the success of our current efforts through our GeoMx Priority Access program, Technology Access Program and Early Access Launch to accelerate adoption of DSP by customers following full commercial launch. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
Vice President, Investor Relations & Corporate Communications